ArticleMolecular neurobiology2026
The Protective Effects of Chlorogenic Acid in Mitigating Gut-Brain Barrier Dysfunction and Autism-Like Symptoms Caused by Early-Life Stress in Mice: A Behavioral, Histopathological, and Molecular Study.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental condition shaped by both genetic predispositions and environmental influences. Early-life stresses (ELS), notably maternal separation (MS), can lead to behavioral impairments similar to core ASD features. Recent research indicates that disruptions in the gut-brain axis may significantly contribute to the neuropsychiatric effects of ELS. This study investigates the role of chlorogenic acid (CGA), a plant-derived polyphenol, in a mouse model of MS-induced ASD-like behaviors. Mice subjected to MS were treated with CGA via intraperitoneal injection over 2 weeks. Behavioral assessments included the open field, passive avoidance, elevated plus maze, marble burying, and three-chamber social interaction tasks. Histologic changes were assessed using H&E staining. Alterations in antioxidant capacity and gene expression were assessed in hippocampal and colonic samples using the FRAP method and qRT-PCR, respectively. CGA administration led to marked improvements in behavioral functions, such as enhanced memory, increased social engagement, and reductions in repetitive, depression, and anxiety-like behaviors. At the molecular level, CGA treatment was associated with lower hippocampal oxidative stress, elevated antioxidant capacity, decreased levels of hippocampal inflammatory markers, alongside beneficial histological changes in hippocampus and colon samples. Furthermore, CGA modulated the expression of tight junction proteins like Claudins (CLDN1, CLDN5, and CLDN12) in the colon and hippocampus, suggesting a protective effect on gut and brain barrier integrity. In summary, MS disrupts the neuro-immune balance and behavior by affecting the gut-brain axis. CGA shows promise in restoring these systems, highlighting its potential as a complementary intervention for conditions related to ASD.
Indexed as
Identifiers
42570177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.